{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T09:59:25Z","timestamp":1779184765928,"version":"3.51.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,1,6]],"date-time":"2017-01-06T00:00:00Z","timestamp":1483660800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s10928-016-9503-z","type":"journal-article","created":{"date-parts":[[2017,1,6]],"date-time":"2017-01-06T03:20:58Z","timestamp":1483672858000},"page":"43-53","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Drug disposition model of radiolabeled etelcalcetide in patients with chronic kidney disease and secondary hyperparathyroidism on hemodialysis"],"prefix":"10.1007","volume":"44","author":[{"given":"Liviawati","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murad","family":"Melhem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raju","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,6]]},"reference":[{"issue":"2","key":"9503_CR1","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1517\/14728214.2015.1018177","volume":"20","author":"M Cozzolino","year":"2015","unstructured":"Cozzolino M, Tomlinson J, Walsh L, Bellasi A (2015) Emerging drugs for secondary hyperparathyroidism. Expert Opin Emerg Drugs 20(2):197\u2013208. doi: 10.1517\/14728214.2015.1018177","journal-title":"Expert Opin Emerg Drugs"},{"issue":"5","key":"9503_CR2","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1124\/mol.115.098392","volume":"88","author":"ST Alexander","year":"2015","unstructured":"Alexander ST, Hunter T, Walter S, Dong J, Maclean D, Baruch A, Subramanian R, Tomlinson JE (2015) Critical cysteine residues in both the calcium-sensing receptor and the allosteric activator AMG 416 underlie the mechanism of action. Mol Pharmacol 88(5):853\u2013865. doi: 10.1124\/mol.115.098392","journal-title":"Mol Pharmacol"},{"key":"9503_CR3","unstructured":"Cunningham J, for the Trial Steering Committee (2015). A long acting intravenous calcimimetic (AMG 416) for secondary hyperparathyroidism (SHPT) in haemodialysed patients [abstract]. Presented at: 52nd European Renal Association\u2014European Dialysis Transplant Association Congress: London"},{"issue":"8","key":"9503_CR4","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1124\/dmd.115.068007","volume":"44","author":"R Subramanian","year":"2016","unstructured":"Subramanian R, Zhu X, Kerr SJ, Esmay JD, Louie SW, Edson KZ, Walter S, Fitzsimmons M, Wagner M, Soto M, Pham R, Wilson SF, Skiles GL (2016) Nonclinical pharmacokinetics disposition, and drug-drug interaction potential of a novel d-amino acid peptide agonist of the calcium sensing receptor AMG 416 (etelcalcetide). Drug Metab Dispos 44(8):1319\u20131331. doi: 10.1124\/dmd.115.068007","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"9503_CR5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ekir.2016.04.002","volume":"1","author":"KZ Edson","year":"2016","unstructured":"Edson KZ, Wu B, Iyer A, Goodman W, Skiles GL, Subramanian R (2016) Determination of etelcalcetide biotransformation and hemodialysis kinetics to guide the timing of its dosing. Kidney Int Rep 1(1):24\u201333. doi: 10.1016\/j.ekir.2016.04.002","journal-title":"Kidney Int Rep"},{"key":"9503_CR6","unstructured":"An open-label, single-dose study to evaluate the pharmacokinetics, biotransformation and excretion of [14C]AMG 416 in patients with end stage renal disease receiving dialysis (2014). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02054572 . Accessed May 10 2016"},{"key":"9503_CR7","doi-asserted-by":"publisher","unstructured":"Subramanian R, Zhu X, Hock B, Sloey BJ, Wu B, Wilson SF, Egbuna O, Slatter JG, Xiao J, Skiles GL (2016) Pharmacokinetics, biotransformation, and excretion of [14C]etelcalcetide (AMG 416) following a single microtracer intravenous dose in patients with chronic kidney disease on hemodialysis. Clin Pharmacokinet [Epub ahead of print]. 1\u201314. doi: 10.1007\/s40262-016-0433-0","DOI":"10.1007\/s40262-016-0433-0"},{"key":"9503_CR8","volume-title":"NONMEM\u00ae Users Guide (1989\u20132009)","author":"SL Beal","year":"2009","unstructured":"Beal SL, Sheiner LB, Boeckmann A, Bauer RJ (2009) NONMEM\u00ae Users Guide (1989\u20132009). Icon Development Solutions, Ellicott City"},{"issue":"6","key":"9503_CR9","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1002\/jcph.460","volume":"55","author":"P Chen","year":"2015","unstructured":"Chen P, Melhem M, Xiao J, Kuchimanchi M, Perez Ruixo JJ (2015) Population pharmacokinetics analysis of AMG 416, an allosteric activator of the calcium-sensing receptor, in subjects with secondary hyperparathyroidism receiving hemodialysis. J Clin Pharmacol 55(6):620\u2013628. doi: 10.1002\/jcph.460","journal-title":"J Clin Pharmacol"},{"key":"9503_CR10","first-page":"392","volume":"88","author":"C Jimenez Diaz","year":"1963","unstructured":"Jimenez Diaz C, Linazasoro JM, Serrano Rios M (1963) Elimination of serum albumin by the feces in nephrosis. Rev Clin Esp 88:392\u2013394","journal-title":"Rev Clin Esp"},{"issue":"9","key":"9503_CR11","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1172\/JCI103183","volume":"34","author":"MA Rothschild","year":"1955","unstructured":"Rothschild MA, Bauman A, Yalow RS, Berson SA (1955) Tissue distribution of I131 labeled human serum albumin following intravenous administration. J Clin Invest 34(9):1354\u20131358","journal-title":"J Clin Invest"},{"issue":"2","key":"9503_CR12","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s11095-015-1791-2","volume":"33","author":"LH Leithold","year":"2016","unstructured":"Leithold LH, Jiang N, Post J, Ziehm T, Schartmann E, Kutzsche J, Shah NJ, Breitkreutz J, Langen KJ, Willuweit A, Willbold D (2016) Pharmacokinetic properties of a novel D-peptide developed to be therapeutically active against toxic beta-amyloid oligomers. Pharm Res 33(2):328\u2013336. doi: 10.1007\/s11095-015-1791-2","journal-title":"Pharm Res"},{"issue":"1","key":"9503_CR13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/03602530600952172","volume":"39","author":"SJ Roffey","year":"2007","unstructured":"Roffey SJ, Obach RS, Gedge JI, Smith DA (2007) What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab Rev 39(1):17\u201343","journal-title":"Drug Metab Rev"},{"key":"9503_CR14","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/ndt\/gft417","volume":"29","author":"KJ Martin","year":"2014","unstructured":"Martin KJ, Bell G, Pickthorn K, Huang S, Vick A, Hodsman P, Peacock M (2014) Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects. Nephrol Dial Transplant 29:385\u2013392. doi: 10.1093\/ndt\/gft417","journal-title":"Nephrol Dial Transplant"},{"issue":"5\u20136","key":"9503_CR15","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.jchromb.2009.12.030","volume":"878","author":"Y Peng","year":"2010","unstructured":"Peng Y, Yang J, Wang Z, Wang J, Liu Y, Luo Z, Wen A (2010) Determination of mildronate by LC-MS\/MS and its application to a pharmacokinetic study in healthy Chinese volunteers. J Chromatogr B Analyt Technol Biomed Life Sci 878(5\u20136):551\u2013556. doi: 10.1016\/j.jchromb.2009.12.030","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"3","key":"9503_CR16","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/cpt1977223364","volume":"22","author":"JJ Schentag","year":"1977","unstructured":"Schentag JJ, Jusko WJ (1977) Renal clearance and tissue accumulation of gentamicin. Clin Pharmacol Ther 22(3):364\u2013370. doi: 10.1002\/cpt1977223364","journal-title":"Clin Pharmacol Ther"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-016-9503-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10928-016-9503-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-016-9503-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T03:27:52Z","timestamp":1498361272000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10928-016-9503-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,6]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["9503"],"URL":"https:\/\/doi.org\/10.1007\/s10928-016-9503-z","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,6]]}}}